Breaking News

Over a quarter ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
One new option listing and six option delistings on July 22nd » 08:30
07/22/19
07/22
08:30
07/22/19
08:30
SLRX

Salarius Pharmaceuticals

$0.62 /

+0.0155 (+2.56%)

, FLKS

Flex Pharma

$0.00 /

+ (+0.00%)

, IHG

InterContinental

$69.61 /

-0.16 (-0.23%)

, NBSE

NeuBase Therapeutics

$4.13 /

-0.07 (-1.67%)

, PKD

Parker Drilling

$18.36 /

+ (+0.00%)

, PULM

Pulmatrix

$0.90 /

-0.0126 (-1.39%)

, SVA

Sinovac Biotech

$0.00 /

+ (+0.00%)

New option listings for…

New option listings for July 22nd include Salarius Pharmaceuticals Inc (SLRX). Option delistings effective July 22nd include Flex Pharma Inc (FLKS), InterContinental (IHG), NeuBase Therapeutics Inc (NBSE), Parker Drilling (PKD), Pulmatrix (PULM), and Sinovac Biotech (SVA).

ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
$0.62 /

+0.0155 (+2.56%)

FLKS Flex Pharma
$0.00 /

+ (+0.00%)

IHG InterContinental
$69.61 /

-0.16 (-0.23%)

07/18/19 RBC Capital
InterContinental downgraded to Underperform from Sector Perform at RBC Capital
07/02/19 UBS
InterContinental downgraded to Sell from Neutral at UBS
06/18/19
Fly Intel: Top five analyst downgrades
06/18/19 Barclays
InterContinental downgraded to Underweight from Equal Weight at Barclays
NBSE NeuBase Therapeutics
$4.13 /

-0.07 (-1.67%)

PKD Parker Drilling
$18.36 /

+ (+0.00%)

05/23/19 Imperial Capital
Parker Drilling price target raised to $34 from $25 at Imperial Capital
05/09/19 Imperial Capital
Parker Drilling price target raised to $25 from $20 at Imperial Capital
04/08/19
Fly Intel: Top five analyst initiations
04/08/19 Imperial Capital
Parker Drilling initiated with an Outperform at Imperial Capital
PULM Pulmatrix
$0.90 /

-0.0126 (-1.39%)

SVA Sinovac Biotech
$0.00 /

+ (+0.00%)

Hot Stocks
Salarius Pharmaceuticals closes strategic merger with Flex Pharma » 08:17
07/22/19
07/22
08:17
07/22/19
08:17
SLRX

Salarius Pharmaceuticals

$0.62 /

+0.0155 (+2.56%)

, FLKS

Flex Pharma

$0.00 /

+ (+0.00%)

Salarius Pharmaceuticals…

Salarius Pharmaceuticals (SLRX) announced that Salarius Pharmaceuticals has closed its merger with Flex Pharma (FLKS) wholly owned subsidiary on July 19, 2019. Flex Pharma, Inc. has been renamed and will operate as Salarius Pharmaceuticals, Inc. The newly combined company will focus on the continued development of Salarius' clinical pipeline, which targets rare, orphan cancers for which no approved targeted treatments are currently available and cancers with a high unmet need. The company will be led by Salarius' current management team under the leadership of President and CEO, David Arthur. Former Flex Pharma President and CEO, William McVicar, Ph.D., will join Salarius' Board of Directors. The company's common stock will trade on the Nasdaq Capital Market under the new ticker symbol "SLRX" beginning on July 22, 2019 and will reflect the previously announced 25:1 reverse stock split that occurred effective as of the close of business on July 19, 2019. Salarius' lead compound, Seclidemstat, targets the epigenetic dysregulation underlying Ewing sarcoma, a devastating pediatric, adolescent, and young adult bone and soft-tissue cancer for which no approved targeted therapies are currently available. Seclidemstat is a differentiated, reversible inhibitor of lysine-specific demethylase 1, or LSD1, which is a widely studied epigenetic enzyme and a validated drug target for clinical development. Salarius is currently enrolling refractory and relapsed Ewing sarcoma patients in an open-label Phase 1 dose escalation/dose expansion study, with potential early cohort data readouts in 2020. Salarius is also conducting a Phase 1 clinical study of Seclidemstat in patients with advanced solid tumors including, but not limited to, prostate, breast, and ovarian cancers.

Hot Stocks
Flex Pharma shareholders approve all proposals relating to Salarius merger » 16:06
07/12/19
07/12
16:06
07/12/19
16:06
FLKS

Flex Pharma

$0.79 /

+0.0381 (+5.07%)

Flex Pharma announced…

Flex Pharma announced that its stockholders approved all proposals relating to its planned merger with Salarius Pharmaceuticals at Flex Pharma's special meeting of stockholders. Flex Pharma will file a Form 8-K to disclose detailed voting results for each proposal. Flex Pharma expects to complete the merger within the next week or two.

Hot Stocks
Flex Pharma announces ISS, Glass Lewis recommend shareholders vote for agenda » 07:05
06/10/19
06/10
07:05
06/10/19
07:05
FLKS

Flex Pharma

$0.52 /

+0.03 (+6.12%)

Flex Pharma announced…

Flex Pharma announced that Institutional Shareholder Services, or ISS, and Glass Lewis recommend that shareholders vote for all agenda items before or at Flex Pharma's June 14 special shareholders meeting. Flex's board also unanimously recommends voting for all agenda items as the best way to preserve future shareholder value. Salarius Pharmaceuticals is a privately held clinical-stage oncology company targeting the epigenetic causes of cancers. ISS said, "The proposed transaction with Salarius appears to offer FLKS shareholders a better potential outcome than FLKS' standalone business. The Flex board also ran a reasonably thorough sale process before identifying this transaction as the best available option. The company contacted or was contacted by 184 parties to solicit interest and the company received proposals from 26 parties. The reverse stock split is necessary to avoid delisting of the company's common stock from the Nasdaq Capital Market. As such, support for this proposal is warranted. In light of the upside potential for Salarius' leading drug candidate, the reasonably thorough sale process used to evaluate alternative options, the positive market reaction, and the downside risk of rejecting this proposal and continuing with FLKS' standalone business plan, support for this proposal is warranted."

ShowHide Related Items >><<
FLKS Flex Pharma
$0.52 /

+0.03 (+6.12%)

06/13/18 Jefferies
Flex Pharma downgraded to Hold from Buy at Jefferies
06/13/18 Ladenburg
Flex Pharma downgraded to Neutral from Buy at Ladenburg

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.